Literature DB >> 32843751

Epidemiology, definition and treatment of complicated urinary tract infections.

Florian M E Wagenlehner1, Truls E Bjerklund Johansen2,3, Tommaso Cai4, Bela Koves5, Jennifer Kranz6,7, Adrian Pilatz8, Zafer Tandogdu2,3,9.   

Abstract

UTIs are amongst the most frequent bacterial infections. However, the clinical phenotypes of UTI are heterogeneous and range from rather benign, uncomplicated infections to complicated UTIs (cUTIs), pyelonephritis and severe urosepsis. Stratification of patients with UTIs is, therefore, important. Several classification systems exist for the description and classification of UTIs, with the common rationale that cUTIs have a higher risk of recurrence or chronification, progression or severe outcome than uncomplicated UTIs. The pathophysiology and treatment of cUTIs and pyelonephritis are driven more by host factors than by pathogen attributes. cUTIs and pyelonephritis are associated with high antimicrobial resistance rates among causative pathogens. However, antimicrobial resistance rates can differ substantially, depending on the population being studied and whether the data being analysed are from surveillance studies, registry data or interventional studies, in which specific inclusion and exclusion criteria are used for patient selection. For example, antibiotic resistance rates are higher in patients with urosepsis than in those with less severe infections. Thus, treatment outcomes differ substantially among studies, ranging from 50% to almost 100% clearance of infection, depending on the patient population analysed, the UTI entities included and the primary outcome of the study. Pyelonephritis and cUTIs have emerged as infection models for the study of novel antibiotics, including extensive investigation of novel substances active against Gram-negative bacteria.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32843751     DOI: 10.1038/s41585-020-0362-4

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN: 1759-4812            Impact factor:   14.432


  89 in total

Review 1.  Epidemiology of urinary tract infections: transmission and risk factors, incidence, and costs.

Authors:  Betsy Foxman; Patricia Brown
Journal:  Infect Dis Clin North Am       Date:  2003-06       Impact factor: 5.982

2.  Guidelines for the evaluation of new anti-infective drugs for the treatment of urinary tract infection: additional considerations.

Authors:  C M Kunin
Journal:  Clin Infect Dis       Date:  1992-12       Impact factor: 9.079

3.  Infectious Diseases Society of America guidelines for the diagnosis and treatment of asymptomatic bacteriuria in adults.

Authors:  Lindsay E Nicolle; Suzanne Bradley; Richard Colgan; James C Rice; Anthony Schaeffer; Thomas M Hooton
Journal:  Clin Infect Dis       Date:  2005-02-04       Impact factor: 9.079

4.  Social and economic burden of recurrent urinary tract infections and quality of life: a patient web-based study (GESPRIT).

Authors:  Florian Wagenlehner; Björn Wullt; Stefania Ballarini; Daniel Zingg; Kurt G Naber
Journal:  Expert Rev Pharmacoecon Outcomes Res       Date:  2017-07-31       Impact factor: 2.217

Review 5.  Acute pyelonephritis among adults: cost of illness and considerations for the economic evaluation of therapy.

Authors:  Patricia Brown; Moran Ki; Betsy Foxman
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

Review 6.  An update on classification and management of urosepsis.

Authors:  Florian M E Wagenlehner; Zafer Tandogdu; Truls E Bjerklund Johansen
Journal:  Curr Opin Urol       Date:  2017-03       Impact factor: 2.309

Review 7.  Urinary tract infection syndromes: occurrence, recurrence, bacteriology, risk factors, and disease burden.

Authors:  Betsy Foxman
Journal:  Infect Dis Clin North Am       Date:  2013-12-08       Impact factor: 5.982

Review 8.  An update on prevention and treatment of catheter-associated urinary tract infections.

Authors:  Peter Tenke; Béla Köves; Truls E B Johansen
Journal:  Curr Opin Infect Dis       Date:  2014-02       Impact factor: 4.915

9.  Resistance patterns of nosocomial urinary tract infections in urology departments: 8-year results of the global prevalence of infections in urology study.

Authors:  Zafer Tandogdu; Mete Cek; Florian Wagenlehner; Kurt Naber; Peter Tenke; Edgar van Ostrum; Truls Bjerklund Johansen
Journal:  World J Urol       Date:  2013-08-24       Impact factor: 4.226

Review 10.  Urinary Tract Infections in Immunocompromised Patients with Diabetes, Chronic Kidney Disease, and Kidney Transplant.

Authors:  Zafer Tandogdu; Tommaso Cai; Bela Koves; Florian Wagenlehner; Truls Erik Bjerklund-Johansen
Journal:  Eur Urol Focus       Date:  2016-10-05
View more
  25 in total

1.  [Urological emergency management : Detection and treatment].

Authors:  Jennifer Kranz; Joachim Steffens; Guido Michels; Laila Schneidewind
Journal:  Med Klin Intensivmed Notfmed       Date:  2021-04-20       Impact factor: 0.840

2.  Modified horseshoe crab peptides target and kill bacteria inside host cells.

Authors:  Anna S Amiss; Jessica B von Pein; Jessica R Webb; Nicholas D Condon; Peta J Harvey; Minh-Duy Phan; Mark A Schembri; Bart J Currie; Matthew J Sweet; David J Craik; Ronan Kapetanovic; Sónia Troeira Henriques; Nicole Lawrence
Journal:  Cell Mol Life Sci       Date:  2021-12-31       Impact factor: 9.261

Review 3.  Cross-roads for meta-analysis and network meta-analysis of H. pylori therapy.

Authors:  David Y Graham; Theodore Rokkas; Ruben Hernaez
Journal:  Gut       Date:  2021-11-08       Impact factor: 23.059

4.  Impact of urinary catheter on resistance patterns and clinical outcomes on complicated urinary tract infection.

Authors:  Carlos Ernesto Lombo Moreno; Oscar Mauricio Muñoz Velandia; Cindy Alejandra Bonilla Sánchez; Juan Sebastián Montealegre Diaz; Javier Ricardo Garzón Herazo
Journal:  Int Urogynecol J       Date:  2022-08-22       Impact factor: 1.932

5.  Preferential catabolism of l- vs d-serine by Proteus mirabilis contributes to pathogenesis and catheter-associated urinary tract infection.

Authors:  Aimee L Brauer; Brian S Learman; Steven M Taddei; Namrata Deka; Benjamin C Hunt; Chelsie E Armbruster
Journal:  Mol Microbiol       Date:  2022-08-15       Impact factor: 3.979

Review 6.  Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021.

Authors:  Qing Wu; Wei Qian; Xiaoli Sun; Shaojie Jiang
Journal:  J Hematol Oncol       Date:  2022-10-08       Impact factor: 23.168

Review 7.  [Complicated urinary tract infections].

Authors:  J Kranz; F M E Wagenlehner; L Schneidewind
Journal:  Urologe A       Date:  2020-12       Impact factor: 0.639

8.  The C5a/C5aR1 Axis Contributes to the Pathogenesis of Acute Cystitis Through Enhancement of Adhesion and Colonization of Uropathogenic E. coli.

Authors:  Kun-Yi Wu; Bo Cao; Chun-Xuan Wang; Xue-Ling Yang; Shu-Juan Zhao; Teng-Yue Diao; Li-Rong Lin; Guo-Xiu Zhao; Wuding Zhou; Ju-Rong Yang; Ke Li
Journal:  Front Cell Infect Microbiol       Date:  2022-03-30       Impact factor: 5.293

Review 9.  Broadening and Enhancing Bacteriocins Activities by Association with Bioactive Substances.

Authors:  Hassan Zgheib; Djamel Drider; Yanath Belguesmia
Journal:  Int J Environ Res Public Health       Date:  2020-10-26       Impact factor: 3.390

10.  Linguistic and clinical validation of the acute cystitis symptom score in German-speaking Swiss women with acute cystitis.

Authors:  Jakhongir F Alidjanov; Ulugbek A Khudaybergenov; Bekhzod A Ayubov; Adrian Pilatz; Stefan Mohr; Julia C Münst; Olivia N Ziviello Yuen; Sabine Pilatz; Corina Christmann; Florian Dittmar; Nodir M Mirsaidov; Mareike Buch-Heberling; Kurt G Naber; Truls E Bjerklund Johansen; Florian M E Wagenlehner
Journal:  Int Urogynecol J       Date:  2021-06-25       Impact factor: 2.894

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.